Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus
- PMID: 2836627
- PMCID: PMC253408
- DOI: 10.1128/JVI.62.7.2490-2497.1988
Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus
Abstract
Our previous study has shown that, although a trypsin-resistant mutant of Sendai virus, TR-2, replicates only in a single cycle in mouse lung with a negligible lesion, the animal acquires a strong immunity against lethal infection with wild-type Sendai virus, suggesting that TR-2 could be used as a new type of live vaccine (M. Tashiro and M. Homma, J. Virol. 53:228-234, 1985). In the present study, we investigated the immunological response elicited in TR-2-infected mice, particularly with respect to cell-mediated immunity. Analyses of cytotoxic activities of spleen cells with 51Cr release assays revealed that Sendai virus-specific T lymphocytes (CTL), in addition to natural killer activity and antiviral antibodies, were induced in DBA/2 and C3H/He mice infected intranasally with TR-2. Proteolytic activation of the fusion glycoprotein F was required for the primary induction of CTL, though not necessarily for stimulation of natural killer and antibody responses. Memory of the CTL induced by TR-2 was long-lasting and was recalled in vivo immediately after challenge with wild-type Sendai virus. In contrast to TR-2, immunization with inactive split vaccine failed to induce the CTL response, but it elicited a high titer of serum antibody and a low level of natural killer activity.
Similar articles
-
A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.J Virol. 1994 May;68(5):3369-73. doi: 10.1128/JVI.68.5.3369-3373.1994. J Virol. 1994. PMID: 8151795 Free PMC article.
-
Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine.Vet Microbiol. 1992 Jan;30(1):1-12. doi: 10.1016/0378-1135(92)90089-c. Vet Microbiol. 1992. PMID: 1311131
-
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2283-7. doi: 10.1073/pnas.88.6.2283. Proc Natl Acad Sci U S A. 1991. PMID: 1848698 Free PMC article.
-
Aerosol vaccination with a sendai virus temperature-sensitive mutant (HVJ-pB) derived from persistently infected cells.J Infect Dis. 1990 Aug;162(2):402-7. doi: 10.1093/infdis/162.2.402. J Infect Dis. 1990. PMID: 1695654
-
Pneumopathogenicity in mice of a Sendai virus mutant, TSrev-58, is accompanied by in vitro activation with trypsin.J Virol. 1988 Aug;62(8):3040-2. doi: 10.1128/JVI.62.8.3040-3042.1988. J Virol. 1988. PMID: 2839720 Free PMC article.
Cited by
-
Comparison of protective effects of serum antibody on respiratory and systemic infection of Sendai virus in mice.Arch Virol. 1989;107(1-2):85-96. doi: 10.1007/BF01313881. Arch Virol. 1989. PMID: 2552964
-
Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus.J Virol. 1997 Jul;71(7):5173-7. doi: 10.1128/JVI.71.7.5173-5177.1997. J Virol. 1997. PMID: 9188584 Free PMC article.
-
A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.J Virol. 1994 May;68(5):3369-73. doi: 10.1128/JVI.68.5.3369-3373.1994. J Virol. 1994. PMID: 8151795 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials